Merck reports data from Phase III gastric cancer treatment trial [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2 (HER2)-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. The randomised, double-blind KEYNOTE-811 trial assessed Keytruda plus trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment. The trial's dual primary endpoints were progression-free survival (PFS) and overall survival (OS), while secondary endpoints comprised objective response rate (ORR), duration of response, and safety. Enrolling 698 subjects, the trial compared Keytruda 200mg given every three weeks in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, versus placebo in combination with trastuzumab and chemotherapy. According to the latest data, the study met its dual primary endpoint of overall survival (OS), showing a significant improvement in patients treated with the Keytruda regimen.
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Cramer says these 10 stocks helped the Dow briefly crack 40,000 [CNBC]CNBC
- Merck (MRK) Crossed Above the 20-Day Moving Average: What That Means for Investors [Yahoo! Finance]Yahoo! Finance
- NMSDC Recognizes 2024 Equity Honors Recipients [Yahoo! Finance]Yahoo! Finance
- XtalPi to Host Inaugural Symposium on the Acceleration of Drug Discovery Through the Use of AI, Automation, and Digitalization [Yahoo! Finance]Yahoo! Finance
- Blackstone Life Sciences Launches Uniquity Bio to Develop Novel Medicines in Immunology & Inflammation [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 4/25/24 - Beat
MRK
Sec Filings
- 5/15/24 - Form 424B5
- 5/15/24 - Form POSASR
- 5/6/24 - Form 144
- MRK's page on the SEC website